Dacula, Hamima .
HRN: 27-98-49 Sex: FemalePatient Encounter
Audit Details
Audit Date
Antimicrobial
Start Date
End Date
Route
Dose
Frequency
Indication Documented
10/22/2025
AMIKACIN 250MG/ML, 2ML (VIAL/AMP)
10/22/2025
10/29/2025
IV
48mg
Q 24
T/C Neonatal Pneumonia
Waiting Final Action
Indication: Empiric Type of Infection: Pneumonia Compliance to guidelines: Compliant To Guidelines
Initial appropriateness: Yes
Final appropriateness: Yes
Overall appropriateness: Yes